Company’s 36-month beta value is 1.47.Analysts have differing opinions on the stock, with 1 analysts rating it as a “buy,” 1 as “overweight,” 1 as “hold,” and 2 as “sell.”
The public float for PRLD is 21.23M, and currently, short sellers hold a 15.70% ratio of that floaft. The average trading volume of PRLD on October 04, 2024 was 279.85K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
PRLD) stock’s latest price update
The stock price of Prelude Therapeutics Inc (NASDAQ: PRLD) has dropped by -6.90 compared to previous close of 2.03. Despite this, the company has seen a fall of -14.48% in its stock price over the last five trading days. globenewswire.com reported 2024-09-13 that – Encouraging signs of anti-tumor activity including objective responses observed in patients with SMARCA4-mutated non-small cell lung cancer (NSCLC) and esophageal cancer in early PRT3789 monotherapy dose escalation
PRLD’s Market Performance
PRLD’s stock has fallen by -14.48% in the past week, with a monthly drop of -63.51% and a quarterly drop of -47.50%. The volatility ratio for the week is 6.75% while the volatility levels for the last 30 days are 12.86% for Prelude Therapeutics Inc The simple moving average for the past 20 days is -39.33% for PRLD’s stock, with a -54.77% simple moving average for the past 200 days.
Analysts’ Opinion of PRLD
Many brokerage firms have already submitted their reports for PRLD stocks, with H.C. Wainwright repeating the rating for PRLD by listing it as a “Buy.” The predicted price for PRLD in the upcoming period, according to H.C. Wainwright is $5 based on the research report published on September 19, 2024 of the current year 2024.
Barclays, on the other hand, stated in their research note that they expect to see PRLD reach a price target of $3. The rating they have provided for PRLD stocks is “Underweight” according to the report published on June 20th, 2024.
JMP Securities gave a rating of “Mkt Outperform” to PRLD, setting the target price at $7 in the report published on March 13th of the current year.
PRLD Trading at -58.38% from the 50-Day Moving Average
After a stumble in the market that brought PRLD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -72.21% of loss for the given period.
Volatility was left at 12.86%, however, over the last 30 days, the volatility rate increased by 6.75%, as shares sank -60.71% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -67.58% lower at present.
During the last 5 trading sessions, PRLD fell by -14.48%, which changed the moving average for the period of 200-days by -56.55% in comparison to the 20-day moving average, which settled at $2.97. In addition, Prelude Therapeutics Inc saw -55.74% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for PRLD
Current profitability levels for the company are sitting at:
- -41.55 for the present operating margin
- 0.57 for the gross margin
The net margin for Prelude Therapeutics Inc stands at -37.92. The total capital return value is set at -0.71. Equity return is now at value -58.45, with -51.44 for asset returns.
Based on Prelude Therapeutics Inc (PRLD), the company’s capital structure generated 0.09 points at debt to capital in total, while cash flow to debt ratio is standing at -5.72. The debt to equity ratio resting at 0.1. The interest coverage ratio of the stock is -101.84.
Currently, EBITDA for the company is -131.11 million with net debt to EBITDA at 0.07. When we switch over and look at the enterprise to sales, we see a ratio of 72.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.83.
Conclusion
In a nutshell, Prelude Therapeutics Inc (PRLD) has experienced a bad performance in recent times. The stock has received mixed “sell” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
